The evolving risk landscape in the life sciences industry
Sedgwick brand protection invites you to discover the latest product-safety challenges and risk management techniques for life sciences, medical device and pharmaceutical companies.
Are you prepared to respond to the evolving risks and changes in the life sciences industry?
Don’t miss out on the insight you need before responding to evolving risks and expected changes in the life sciences regulatory landscape. Within the recorded webinar, Kate Hardey, Partner at McGuire Woods LLP, shares her insight based on more than 25 years of law firm, in-house and healthcare industry experience.
During the 30-minute session, we’ve examined the hottest topics at the U.S. Food and Drug Administration, including:
- Opportunities and risks associated with Emergency Use Authorizations, particularly for COVID-19 tests, treatments and vaccines
- What virtual audits mean for the future of warning letters and inspection priorities
- What global suppliers and manufacturers need to know about virtual inspections
- Changes expected under the Biden administration
- What’s next for the cannabis and CBD industries
For your convenience, we have also published a summary of the key highlights. This document captures the insight shared along with additional resources to monitor for the latest information needed to prepare for your next product safety crisis.
This is your chance to access the information you need to best mitigate, prepare for, and respond to crisis in the life sciences, medical device and pharmaceutical industries.